What science
can do


Annual Report & Form 20-F
Information 2017

01

Overview

This Annual Report quick-read provides top-level information on our business and the progress we have made in 2017 in pushing the boundaries of science to deliver life-changing medicines.


Watch the video on 'what science can do'

02

Chairman & CEO



One of the Board’s basic responsibilities is to set our strategy and monitor progress towards meeting our objectives, so that we bring our science to patients, create value for society, and reward you, our shareholders.

Leif Johansson Chairman

2017 represented a defining year for AstraZeneca. 2018 will be equally important as we seek to deliver the full potential of our medicines and ensure we deliver our science to patients around the world.

Pascal Soriot CEO

03

Financial Highlights


In 2017, our financial performance reflected the launch of several new medicines, the strong performance of our Growth Platforms and the continued impact from patent expiries; most notably for Crestor and Seroquel XR in the US.


Key Highlights

Total Revenue

$22.5bn

 

Net cash flow from operating activities

$3.6bn

 

Reported operating profit

$3.7bn

 

Core operating profit

$6.9bn

 

Reported EPS

$2.37

 

Core EPS

$4.28

 

04

At a Glance

We are a global biopharmaceutical business delivering medicines to patients through innovative science and excellence in development and commercialisation.

Product Sales

$20,152m

2016: $21,319m
2015: $23,641m



By therapeutic area


By geography



61,100

employees

100%

of employees trained in new Code of Ethics

84%

Maintained listing in the Dow Jones Sustainability World and Europe Indices. Our score of 84% was within two percentage points of sector’s best score




Dividend per Ordinary Share

for 2017


1st interim dividend

$0.90

Pence: 68.9
SEK: 7.40
Payment date: 11 September 2017

2nd interim dividend

$1.90

Pence: 133.6
SEK: 14.97
Payment date: 19 March 2018

Total

$2.80

Pence: 202.5
SEK: 22.37


05

Strategy

We announced our strategy for returning to growth in 2013. We moved on from the first phase in our journey, focused on rebuilding our pipeline, in 2015. The second stage is crucial as we drive our Growth Platforms forward, continue to launch new medicines and make them available to patients. As we look ahead to 2020 and beyond, continued investment in our pipeline will keep us on track to return to sustainable growth in line with our targets.

In 2017, our strategic priorities were focused under the three pillars described below.

  • Achieve Scientific Leadership

    We are focusing our science on three therapy areas and accelerating our pipeline. We are also transforming our way of working.


  • Return to Growth

    We are focusing on our Growth Platforms and transforming the business through specialty care, devices and biologic medicines. Targeted business development reinforces our efforts.


  • Be a Great Place to Work

    We are evolving our culture and simplifying our business. We want to attract and retain the best talent. We also want to do business sustainably.



Therapy Area Highlights

We have transformed our drugs portfolio by focusing on three therapy areas: Oncology, Cardiovascular & Metabolic Diseases (CVMD) and Respiratory, while being selectively active in Other Disease Areas.